Spruce Biosciences/$SPRB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Spruce Biosciences
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
Ticker
$SPRB
Sector
Primary listing
Employees
8
Headquarters
Website
SPRB Metrics
BasicAdvanced
$155m
-
-$50.83
3.82
-
Price and volume
Market cap
$155m
Beta
3.82
52-week high
$240.00
52-week low
$7.26
Average daily volume
78k
Financial strength
Current ratio
5.167
Quick ratio
5.107
Long term debt to equity
0.986
Total debt to equity
1.731
Interest coverage (TTM)
-317.92%
Profitability
EBITDA (TTM)
-28.592
Management effectiveness
Return on assets (TTM)
-36.41%
Return on equity (TTM)
-109.24%
Valuation
Price to book
1.85
Price to tangible book (TTM)
1.85
Price to free cash flow (TTM)
-1.315
Free cash flow yield (TTM)
-76.03%
Free cash flow per share (TTM)
-43.474
Growth
Earnings per share change (TTM)
-47.27%
3-year earnings per share growth (CAGR)
-29.85%
SPRB News
AllArticlesVideos
Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Business Wire·1 week ago
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
Business Wire·2 months ago
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Spruce Biosciences stock?
Spruce Biosciences (SPRB) has a market cap of $155M as of April 28, 2026.
What is the P/E ratio for Spruce Biosciences stock?
The price to earnings (P/E) ratio for Spruce Biosciences (SPRB) stock is 0 as of April 28, 2026.
Does Spruce Biosciences stock pay dividends?
No, Spruce Biosciences (SPRB) stock does not pay dividends to its shareholders as of April 28, 2026.
When is the next Spruce Biosciences dividend payment date?
Spruce Biosciences (SPRB) stock does not pay dividends to its shareholders.
What is the beta indicator for Spruce Biosciences?
Spruce Biosciences (SPRB) has a beta rating of 3.82. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.